TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19506839
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg pramipexole
Study: 19506839
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg pramipexole
Study: 19506839
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg pramipexole
Study: 16686721
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg GYKI‐16084
Study: 16686721
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg GYKI‐16084
Study: 2183873
Drug: Didox 6
Normalized name: Digox
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didox 6 g m‐2 by 36 h infusion
Study: 2183873
Drug: Didox 6
Normalized name: Digox
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didox 6 g m‐2 by 30 min infusion
Study: 7463326
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of dexamethasone at 11 pm (Treatment A)
Study: 7463326
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of dexamethasone at 11 pm (Treatment B)
Study: 7463326
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of dexamethasone at 11 pm and an additional 1 mg at 6 am (Treatment C)
Study: 29170998
Drug: Isotonic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic maintenance fluid (NaCl 0.9% in glucose 5% with 40 mmol L‐1 potassium chloride)
Study: 29170998
Drug: Hypotonic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic maintenance fluid (premixed solution containing 54 mmol L‐1 sodium, 55 mmol L‐1 chloride and 26 mmol of potassium)
Study: 22068990
Drug: No surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surgery (best medical therapy)
Study: 16905810
Drug: Curiosin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curiosin and plasma-therapy
Study: 15688984
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) treatment at a dose of 4 g/day i.v. for the first 24 hours after admission
Study: 15688984
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without MgSO4
Study: 11343038
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin (2.0 clinical units per kg as a single dose)
Study: 9389261
Drug: suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.0 mg kg-1
Study: 9389261
Drug: rocuronium 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.9 mg kg-1
Study: 9389261
Drug: mivacurium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.1 mg kg-1 with rocuronium 0.3 mg kg-1
Study: 9389261
Drug: mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.15 mg kg-1 with rocuronium 0.45 mg kg-1
Study: 9389261
Drug: mivacurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.2 mg kg-1
Study: 9389261
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg kg-1
Study: 9389261
Drug: rocuronium 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.45 mg kg-1 and mivacurium 0.15 mg kg-1
Study: 7893583
Drug: Idrapril calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrapril calcium 100 mg twice daily
Study: 7893583
Drug: Idrapril calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrapril calcium 200 mg twice daily
Study: 7893583
Drug: Idrapril calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrapril calcium 400 mg twice daily
Study: 7893583
Drug: Idrapril calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idrapril calcium (all doses)
Study: 17906871
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg) plus visual sexual stimulation (VSS)
Study: 10638606
Drug: Neostigmine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.0 mg i.v. over 3-5 min
Study: 10638606
Drug: Neostigmine (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (open-label treatment)
Study: 1473540
Drug: Ceftazidime monotherapy
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime monotherapy (CAZ)
Study: 30052230
Drug: Inhaled levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levosimendan administered 6th hourly over 24 h
Study: 30052230
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan infusion at 0.1 mcg/kg/min for 24 h
Study: 30052230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not explicitly defined, but implied as the comparison between inhaled and intravenous levosimendan)
Study: 24560584
Drug: Symbiotic Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic Drink (administered via enteral feeding during the first 7 days)
Study: 9814627
Drug: Enalapril/hydrochlorothiazide (20/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril/hydrochlorothiazide (20/6 mg) daily
Study: 9814627
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) daily
Study: 2503631
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (N=13)
Study: 2503631
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (N=11)
Study: 2503631
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (N=17)
Study: 2503631
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) (N=10)
Study: 21346607
Drug: ABT‐925 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐925 50 mg QD
Study: 21346607
Drug: ABT‐925 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐925 150 mg QD
Study: 17356091
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no inhaled medication)
Study: 922328
Drug: 500 IU
Normalized name: Vitamin E 500 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU vitamin D daily
Study: 922328
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU vitamin D daily
Study: 26714522
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (treatment-as-usual)
Study: 19863739
Drug: Reduced-dose rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose rocuronium (0.45 mg x kg(‐1))
Study: 19863739
Drug: Standard-dose rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rocuronium (0.6 mg.kg(‐1))
Study: 17564674
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration (WBV) at 30 Hz; 3.5 g (1 g=9.81 m.s2)
Study: 16282676
Drug: Doxercalciferol at
Normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxercalciferol at 35%, 50%, or 65% of paricalcitol dose for 6 weeks
Study: 12242054
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg and 1200 mg mifepristone
Study: 10235156
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11)
Study: 10235156
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (in the nonrandomized part)
Study: 10235156
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy and RT only
Study: 6123287
Drug: Oxatomide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide (30 mg bid)
Study: 21287904
Drug: Concurrent peer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent peer review visits
Study: 12759845
Drug: Prophylaxis treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis treatments
Study: 9527146
Drug: 24 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g/day piracetam
Study: 9527146
Drug: 16.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.8 g/day piracetam
Study: 9527146
Drug: 9.6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6 g/day piracetam
Study: 7605861
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of famotidine 40 mg/day
Study: 7246468
Drug: Hypnotic sensory
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic sensory imagery conditioning program (three-week duration, daily sessions with three conditioning images and self-hypnotic practice)
Study: 24450252
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin (TAM) 0.4 mg daily
Study: 24450252
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens (SR) 320 mg daily
Study: 24450252
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin (TAM) 0.4 mg daily + Serenoa repens (SR) 320 mg daily
Study: 21404452
Drug: Continuous low-volume
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low-volume infusion of hydroxyethyl starch (HES) at a dose of 15 ml/kg/day
Study: 12162272
Drug: Algorithm dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm dosing of acenocoumarol
Study: 12162272
Drug: Routine dosing
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dosing of acenocoumarol
Study: 2363117
Drug: i.v. low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. low-dose aspirin
Study: 2363117
Drug: i.v. isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. isosorbide dinitrate and oral diltiazem
Study: 12587621
Drug: 5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microg/kg per day of intravenous rGCSF once daily for 3 days
Study: 29775141
Drug: Structured group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured group reminiscence therapy for 8 weeks
Study: 23478699
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein diet (< 22% daily energy intake) + Resistance Training (RT)
Study: 23478699
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (> 22% daily energy intake) + Resistance Training (RT)
Study: 23478699
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein diet (< 22% daily energy intake) + Habitual activity (Control)
Study: 23478699
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (> 22% daily energy intake) + Habitual activity (Control)
Study: 20034682
Drug: Injected activated
Normalized name: eptacog alfa activated Injection [Novoseven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected activated macrophage suspension (AMS)
Study: 12011547
Drug: Echovist-300 with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echovist-300 with VM for 5 s starting 5 s after injection
Study: 12011547
Drug: Echovist-200 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echovist-200 with VM for 5 s starting 5 s after injection
Study: 12011547
Drug: Echovist-300 with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echovist-300 with VM for 5 s starting with the beginning of injection
Study: 12011547
Drug: Echovist-300 with
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echovist-300 with VM for 5 s starting 10 s after injection
Study: 12011547
Drug: Echovist-200 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echovist-200 with VM for 5 s starting with the beginning of injection
Study: 10424515
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (RATG) induction therapy (1.5 mg/kg/d for 3 days)
Study: 10424515
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression alone (no induction therapy)
Study: 10424515
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin (RATG) induction therapy
Study: 31627773
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents (specific agents not detailed)
Study: 29307310
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green coffee bean extract (GCE) 400 mg twice per day for 8 weeks
Study: 27175447
Drug: Heat-killed Lactobacillus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed Lactobacillus plantarum L-137 (HK L-137) 10 mg daily for 12 weeks
Study: 30917927
Drug: BAY 85-8501
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 85-8501 (1 mg once daily for 28 days)
Study: 25933488
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (7000 μg retinol equivalents)
Study: 19928386
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (fixed sleep schedule consistent with average baseline, no TIB restriction)
Study: 16355285
Drug: Bumetanide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (2 mg/day)
Study: 11125713
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg glycyrrhizic acid/kg body weight
Study: 11125713
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glycyrrhizic acid/kg body weight
Study: 11125713
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg glycyrrhizic acid/kg body weight
Study: 11125713
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg glycyrrhizic acid/kg body weight
Study: 9042977
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 500 mg b.d.
Study: 9042977
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg q.d.s.
Study: 29901507
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMF) treatment
Study: 30316696
Drug: Dexketoprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen (1 mg kg–1 IV; administered every 8 hours)
Study: 30316696
Drug: Methadone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.2 mg kg–1 IV; administered every 4 hours)
Study: 19034870
Drug: Epoetin-alpha (EPO-alpha)
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha (EPO-alpha) to maintain hemoglobin levels in the range 12-14 g/dL, median final dose 2,000 IU/week.
Study: 19034870
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment unless hemoglobin decreased to 9.0 g/dL).
Study: 19034870
Drug: Epoetin-alpha (EPO-alpha)
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha (EPO-alpha) treatment group.
Study: 17163135
Drug: Twinrix and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twinrix and monovalent vaccines
Study: 2082318
Drug: Acetaminophen-codeine 600
Normalized name: acetaminophen / codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-codeine 600 mg plus 60 mg
Study: 117953
Drug: Insulin induced
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin induced hypoglycaemia
Study: 27931291
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 µg once daily (n = 25)
Study: 16332600
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5FU/levamisole for 12 months, n = 444; 5FU/leucovorin for 4-5 months, n = 262; 5FU/leucovorin with +/- levamisole, n = 397)
Study: 12006716
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate 300 microg 6 times daily for 2 years
Study: 12006716
Drug: Subcutaneous Suprefact
Normalized name: Suprefact
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Suprefact Depot 6.3 mg every 8 weeks for the third year
Study: 12006716
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment in addition to pubertal inhibition (randomized in half of the girls)
Study: 15159227
Drug: Moderate n-6
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Study: 15159227
Drug: High n-6
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Study: 15159227
Drug: 4.0 g
Normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid) after 6 weeks of dietary intervention
Study: 11953878
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg intravenous clodronate
Study: 11953878
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg intravenous clodronate
Study: 11953878
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg intravenous clodronate
Study: 11953878
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg intravenous clodronate
Study: 2146057
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg every 12 hours)
Study: 369651
Drug: Acarbose (alpha-glucosidehydrolase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (alpha-glucosidehydrolase inhibitor) taken with food
Study: 30986302
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 16.1 mg of ASAL‐HM
Study: 30986302
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of 8.0 mg of HM (control)
Study: 30986302
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of ASAL‐HM
Study: 30055692
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection with 40 mg triamcinolone acetonide
Study: 30055692
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection with 1.25 mg bevacizumab
Study: 30055692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subconjunctival triamcinolone acetonide and intravitreal bevacizumab
Study: 27817811
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 9/9.6 μg
Study: 27817811
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 4.6/9.6 μg
Study: 27817811
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 2.4/9.6 μg
Study: 27817811
Drug: GFF MDI
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI 1.2/9.6 μg
Study: 27817811
Drug: Open-label tiotropium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label tiotropium 18 μg
Study: 22301084
Drug: Buprenorphine induction
Normalized name: buprenorphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine induction for prescription opioid users
Study: 10436979
Drug: Zhuling polysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuling polysaccharides combined with hepatitis B vaccine (group I)
Study: 10436979
Drug: LAK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAK cells induced by interleukin‐2 (IL‐2) transfusion therapy (group II)
Study: 29279299
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic therapy (target HbA1c <6.0%)
Study: 27494777
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks for ≤7.5 years